Roche, obesity and Zealand

Roche secures Zealand obesity drug candidate for up to $5.3 billion
Roche acquired rights to an obesity therapy by Danish biotech firm Zealand Pharma in a collaboration deal worth up to $5.3 billion, as the Swiss pharmaceutical company seeks to boost its prospects in the booming weight-loss market.
Roche partners with Zealand Pharma to push forward obesity drug
Roche partnered with Zealand Pharma to license an experimental weight loss drug for $1.65 billion upfront, expanding its obesity pipeline.
Roche, Zealand Pharma in $5.3 Billion Pact for Obesity Drugs
Roche Holding AG licensed a new weight-loss drug from Zealand Pharma A/S for as much as $5.3 billion, bolstering the Swiss drugmaker’s effort to get into a hot market dominated by Novo Nordisk A/S and Eli Lilly & Co.
Roche pairs with Zealand Pharma on obesity drug candidate
Roche has entered an exclusive collaboration and licensing agreement with Danish obesity drug maker Zealand Pharma to co-develop petrelintide as an obesity therapy drug, the Swiss company said on Wednesday.
Roche signs biggest-ever obesity drug deal
Roche has signed the biggest-ever obesity drug deal with a $5.3bn licensing agreement for a next-generation treatment from Danish biotech Zealand Pharma. The Swiss pharmaceutical company will collaborate with Zealand on petrelintide,
Roche Agrees to Develop Weight-Loss Therapy With Zealand Pharma
The companies agreed to share profits for the therapy equally in the U.S. and Europe, but Roche will have exclusive rights to commercialization in the rest of the world.
Roche to develop, commercialize obesity drug with Zealand Pharma
Roche has entered an exclusive collaboration and licensing agreement with Danish obesity drug maker Zealand Pharma to co-develop petrelintide as an obesity therapy drug, the Swiss company said on Wednesday.
Compound versions of some weight loss drugs to be restricted
Compounded versions of popular drugs used for weight loss including Wegovy and Zepbound will soon no longer be available ...
BioPharma Dive16h
Viking inks CordenPharma deal to boost obesity drug supply
The biotech will commit $150 million to an alliance that hands it significant production capacity for a closely watched ...
InnovationRx: Eli Lilly Has Stockpiled Nearly $550 Million Of Its Next Obesity Drug
In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...
Is the obesity drug market still a duopoly?
Novo Nordisk and Eli Lilly currently control 99% of the market, but their dominance may weaken as new entrants introduce ...
Who can get weight loss drugs on the NHS in Scotland?
Very few people are currently being prescribed drugs for weight loss on the NHS in Scotland, research by BBC Scotland News ...